Report: Midcap biotechs boost R&D investment in Q3 2012

03/8/2013 | American City Business Journals

Midcap biotech companies spent $746.8 million on research and development in the third quarter of 2012, an increase from $621.1 million in the same period of 2011, according to a report from GlobalData. The focus of research programs is cancer treatment, "which is driving peer group R&D expenses higher," an analyst said.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN